Business Context and Reporting Period
This Form 6-K filing by Royal Dutch Shell plc covers the month of January 2013, with the report dated January 30, 2013. The filing serves as a Director Declaration pursuant to Listing Rule 9.6.14R regarding a change in the company's board composition.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a corporate governance disclosure and does not contain financial performance data.
Material Changes
The material change disclosed is the appointment of Hans Wijers, Deputy Chairman and Senior Independent Director of Shell, as a Non-executive Director of GlaxoSmithKline plc, effective April 1, 2013.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document is strictly limited to the director appointment announcement.
Investor Verification Checklist
- Verify the effective date of Hans Wijers' new role at GlaxoSmithKline plc (April 1, 2013).
- Confirm whether this external appointment impacts Mr. Wijers' availability or duties as a Senior Independent Director at Shell.
- Note that this filing does not update Shell's financial results; refer to the most recent Form 20-F or quarterly reports for financial data.